Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2020

June 2020 | 103 pages | ID: L6BBB1759DEEN
Global Markets Direct

Abstracts

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure - Pipeline Review, H1 2020, provides an overview of the Liver Failure (Gastrointestinal) pipeline landscape.
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Liver Failure (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Failure (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Liver Failure (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Liver Failure (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Liver Failure (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Liver Failure (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Liver Failure (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Liver Failure (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
Liver Failure (Hepatic Insufficiency) - Drug Profiles
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Arch Biopartners Inc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Bristol-Myers Squibb Co, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by EA Pharma Co Ltd, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by HepaRegeniX GmbH, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Hepatx Corp, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Mallinckrodt Plc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Proterris Inc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Rejuvenation Technologies Inc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by RHEACELL GmbH & Co KG, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Steminent Biotherapeutics Inc, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Tianjin Weikai Bioeng Ltd, H1 2020
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2020
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2020
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Arch Biopartners Inc
Bristol-Myers Squibb Co
EA Pharma Co Ltd
HepaRegeniX GmbH
Hepatx Corp
Immune Pharmaceuticals Inc
Mallinckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
PledPharma AB
Promethera Biosciences SA
Proterris Inc
Rejuvenation Technologies Inc
RHEACELL GmbH & Co KG
Steminent Biotherapeutics Inc
Takeda Pharmaceutical Co Ltd
Tianjin Weikai Bioeng Ltd
Unicyte AG